急性骨髓性白血病市场:KOL的洞察

本报告研究了全球急性髓系白血病市场，提供了市场概况，以及商业推出的疗法、管道趋势和未来前景。

目录

摘要整理

急性骨髓性白血病的治疗流程

调查目的

BCL-2抑制剂

• 已通过核准药物
  • venkurekusuta/venkurisuto(Venetoclax;AbbVie/Roche)

FLT3抑制剂

• 已通过核准药物
  • Rydapt(midosutaurin;Novartis)，Xospata(Gilteritinib;Astellas Pharma)，及Vanflyta(kizaruchinibu;Daiichi Sankyo)
• 开发平台药物
  • kurenoranibu(AROG Pharmaceuticals/Pfizer)

IDH1/2抑制剂

• 已通过核准药物
  • Tivovo（ivosidenib; 施维雅）、伊迪法（Enasidenib; 施维雅/百时美施贵宝）和Leslichia（Altersidenib; Rigel Pharmaceuticals/Forma Therapeutics）

新处方的化疗及低甲基化剂

• 已通过核准药物
  • Vyxeos(注射用道诺霉素+ Cytarabine微脂体;Jazz Pharmaceuticals)
  • onuregu(CC-486/口服Azacitidine;Bristol Myers Squibb)
  • Inqovi/Inaqovi(ASTX727，Astex Pharmaceuticals/Otsuka Pharmaceuticals)

hedgehog抑制剂

• 已通过核准药物
  • Daurismo(gurasudejibu，Pfizer)

抗体药物复合体及放射性免疫复合体

• 已通过核准药物
  • Mylotarg(Gemtuzumab Ozogamicin;Pfizer)
• 开发平台药物
  • Iomab-B（131I Apamistamab，Actinium Pharmaceuticals）
  • Actimab-A（林妥珠单抗-AC225; Actinium Pharmaceuticals（锒化製药）

其他的作用机制

• 开发平台药物
  • Uproleseran （GlycoMimetics）
  • Garimpepimut-S（塞拉斯生命科学）
  • Revmenib（Syndax Pharmaceuticals）和Difutomenib（Kura Oncology）

AML治疗的未来趋势与机会

附录

How might the treatment paradigm change for AML? Why do KOLs say Roche/AbbVie's Venclexta/Venclyxto and azacitidine will remain the standard of care for newly diagnosed AML patients ineligible for intensive chemotherapy? Why do experts believe Novartis' Rydapt could come under pressure from Astellas Pharma's Xospata? KOLs are eagerly anticipating trial results for Syndax Pharmaceuticals' revumenib - why? KOLs critically assess the prospects of launched and pipeline therapies.

Key questions answered:

• What factors do US KOLs say are limiting uptake of Daiichi Sankyo's FLT3 inhibitor Vanflyta?
• Why do experts see a limited role for AROG Pharmaceuticals/Pfizer's FLT3 inhibitor crenolanib?
• Why would most KOLs use Rigel Pharmaceuticals/Forma Therapeutics' Rezlidhia over Servier's Tibsovo in R/R IDH1 mutated AML?
• What Phase III trial data do KOLs say could see Jazz Pharmaceuticals' Vyxeos become the standard chemotherapy backbone?
• What practical challenges do experts identify for Actinium Pharmaceuticals' Iomab-B and Actimab-A pipeline therapies?
• What underpins KOLs' opinions that menin inhibitors could have a practice-changing impact?

Key brands covered in this report:

Table of Contents

Executive summary (10)

Treatment algorithm for acute myeloid leukaemia

Research objectives (10)

BCL-2 inhibitors (18)

• Approved drugs (18)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (18)

FLT3 inhibitors (23)

• Approved drugs (17)
  • Rydapt (midostaurin; Novartis), Xospata (gilteritinib; Astellas Pharma) and Vanflyta (quizartinib; Daiichi Sankyo) (17)
• Pipeline drugs (6)
  • Crenolanib (AROG Pharmaceuticals/Pfizer) (6)

IDH1/2 Inhibitors (19)

• Approved drugs (19)
  • Tibsovo (ivosidenib; Servier), Idhifa (enasidenib; Servier/Bristol Myers Squibb) and Rezlidhia (olutasidenib; Rigel Pharmaceuticals/Forma Therapeutics) (19)

Novel formulation chemotherapies and hypomethylating agents (24)

• Approved drugs (24)
  • Vyxeos (daunorubicin + cytarabine liposome for injection; Jazz Pharmaceuticals) (11)
  • Onureg (CC-486/oral azacitidine; Bristol Myers Squibb) (5)
  • Inqovi/Inaqovi (ASTX727; Astex Pharmaceuticals/Otsuka Pharmaceuticals) (8)

Hedgehog inhibitors (4)

• Approved drugs (4)
  • Daurismo (glasdegib; Pfizer) (4)

Antibody-drug conjugates and radioimmunoconjugates (15)

• Approved drugs (4)
  • Mylotarg (gemtuzumab ozogamicin; Pfizer) (4)
• Pipeline drugs (11)
  • Iomab-B (131I apamistamab; Actinium Pharmaceuticals) (6)
  • Actimab-A (lintuzumab-Ac225; Actinium Pharmaceuticals) (5)

Other mechanisms of action (21)

• Pipeline drugs (21)
  • Uproleselan (GlycoMimetics) (6)
  • Galinpepimut-S (SELLAS Life Sciences) (6)
  • Revumenib (Syndax Pharmaceuticals) and ziftomenib (Kura Oncology) (9)

Future trends and opportunities in AML treatment (4)

Appendix (4)

• KOL details (4)
  • KOLs from the US (2)
  • KOLs from Europe (1)